Evidence map›Paper›PMID 40060625›Full record

ArticlebioRxiv : the preprint server for biology2025

Targeting tGLI1, a novel mediator of tumor therapeutic resistance, using Ketoconazole sensitizes glioblastoma to CDK4/6 therapy and chemoradiation.

Yang Yu, Austin Arrigo, Ankush Chandra, Chuling Zhuang, Mariana K Najjar, Munazza S Khan, Dongqin Zhu, Antonio Dono, Roy E Strowd, Nitin Tandon and 5 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Coupling of stemness maintenance with cell cycle control in stem cells.Frontiers in cell and developmental biology · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Yang YuDepartment of Cancer Biology, Wake Forest School University of Medicine, Winston-Salem, NC.
Austin ArrigoVivian L. Smith Department of Neurosurgery, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, USA.
Ankush ChandraVivian L. Smith Department of Neurosurgery, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, USA.
Chuling ZhuangVivian L. Smith Department of Neurosurgery, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, USA.
Mariana K NajjarVivian L. Smith Department of Neurosurgery, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, USA.
Munazza S KhanVivian L. Smith Department of Neurosurgery, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, USA.
Dongqin ZhuDepartment of Cancer Biology, Wake Forest School University of Medicine, Winston-Salem, NC.
Antonio DonoVivian L. Smith Department of Neurosurgery, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, USA.
Roy E StrowdDepartment of Neurology, Wake Forest University School of Medicine, Winston-Salem, NC.
Nitin TandonVivian L. Smith Department of Neurosurgery, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, USA.
Jay-Jiguang ZhuVivian L. Smith Department of Neurosurgery, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, USA.
Sigmund H HsuVivian L. Smith Department of Neurosurgery, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, USA.
Yoshua EsquenaziVivian L. Smith Department of Neurosurgery, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, USA.
Michael ChanDepartment of Radiation Oncology, Wake Forest University School of Medicine, Winston-Salem, NC.
Hui-Wen LoDepartment of Cancer Biology, Wake Forest School University of Medicine, Winston-Salem, NC.ORCID 0000-0002-0681-7914

Funding

Roles of tGLI1 and microRNA Network in Breast Cancer Brain MetastasisR01CA228137 · NCI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI LO, HUI-WEN, WATABE, KOUNOSUKE · 2020 to 2025
$2.1M
Understanding and overcoming resistance of breast cancer brain metastases to RET inhibitionR21CA286225 · NCI · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI LO, HUI-WEN · 2024 to 2024
$401k
Research Training for Residents & Fellows in Neurological DisordersUE5NS113757 · NINDS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI Samden Lhatoo, NITIN TANDON · 2024 to 2026
$353k
NCI NIH HHS R01 CA228137NCI NIH HHS R21 CA286225NINDS NIH HHS UE5 NS113757
6 · The paper itself

Abstract

Glioblastoma (GBM) remains the most aggressive primary brain tumor in adults, with no effective treatments. While cyclin-dependent kinase 4/6 inhibitors (CDK4/6is) show clinical promise in some cancers, they have not significantly improved survival in GBM patients. This lack of response is attributed to the treatment-resistant glioma stem cell (GSC) population. We previously identified truncated glioma-associated oncogene homolog 1 (tGLI1) as a novel transcription factor promoting GSCs; however, its role in CDK4/6i resistance has never been investigated in any cancer type. Here, we found positive correlations between tGLI1 and CDK4/6 therapeutic resistance in patient datasets and

Identifiers

PMID40060625
PMCPMC11888219

What Socratic holds

Textmetadata
LicenceCC BY-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.